UBS Group
ESLA icon

UBS Group’s Estrella Immunopharma ESLA Stock Holding History

UBS Group’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$633 Sell
1,356
-365
-21% -$260 ﹤0.01% 10540
2026
Q2 		$1.79K Sell
1,721
-13,358
-89% -$17.5K ﹤0.01% 9470
2026
Q1 		$16K Buy
15,079
+11,892
+373% +$13.7K ﹤0.01% 8089
2025
Q4 		$4.97K Sell
3,187
-47,160
-94% -$89.2K ﹤0.01% 8749
2025
Q3 		$57.9K Sell
50,347
-22,426
-31% -$21.5K ﹤0.01% 7463
2025
Q2 		$69.9K Buy
72,773
+31,739
+77% +$30.8K ﹤0.01% 7516
2025
Q1 		$38K Sell
41,034
-24,133
-37% -$26.5K ﹤0.01% 7783
2024
Q4 		$78.2K Buy
65,167
+58,644
+899% +$59.1K ﹤0.01% 7030
2024
Q3 		$7.57K Buy
+6,523
New +$8.39K ﹤0.01% 7894
2024
Q1 		– Sell
-303
Closed -$336 – 9476
2023
Q4 		$336 Buy
+303
New +$458 ﹤0.01% 8718
2023
Q1 		– Sell
-756
Closed -$7.78K – 9787
2022
Q4 		$7.78K Buy
756
+310
+70% +$3.15K ﹤0.01% 8860
2022
Q3 		$4K Buy
+446
New +$4.48K ﹤0.01% 9349

Other funds holding ESLA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

UBS Group's ESLA Position: Q3 2026 in Review

UBS Group reduced its Estrella Immunopharma (ESLA) stake by 21% in Q3 2026, selling an estimated $260 and leaving 1,356 shares worth $633. The position accounts for ﹤0.01% of the portfolio, ranked #10540.

UBS Group first reported a position in ESLA in Q3 2022 and has held it in 12 quarters since. The position peaked at $78.2K in Q4 2024. 11 funds tracked by Wall St. Rank hold ESLA as of Q3 2026.

  • UBS Group held 1,356 shares of Estrella Immunopharma worth $633 as of Q3 2026.
  • UBS Group sold 365 Estrella Immunopharma shares in Q3 2026, an estimated $260.
  • Estrella Immunopharma made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10540 holding.
  • UBS Group first reported a position in Estrella Immunopharma in Q3 2022 and has held it in 12 quarters since.
  • UBS Group's Estrella Immunopharma position peaked at $78.2K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.